



\$125 Million
Private Placement

svb Securities
Placement Agent
June 2023

SVB Securities Serves as Placement Agent for Morphimmune's \$125 Million Private Placement

Key Transaction Highlights

- On June 29, 2023, concurrent with the announcement of its merger with Immunome (Nasdaq: IMNM), Morphimmune announced a \$125 million private placement.
- Well oversubscribed with participation from new and existing investors, including Enavate Sciences, EcoR1 Capital, Redmile Group, Janus Henderson Investors, Avidity Partners, Woodline Partners LP, and other leading institutional investors
- The proceeds from the private placement will be used to continue development of the lead assets in the combined company's pipeline, to continue to advance the company's platforms, and for general working capital purposes.
- Both the merger and private placement are expected to close by the end of Q4 2023.
- This is SVB Securities' 1st transaction for Morphimmune.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON
53 State Street
40th Floor
Boston, MA 02109

CHARLOTTE
2151 Hawkins Street
Suite 1025
Charlotte, NC 28203

NASHVILLE
40 Burton Hills Boulevard
Suite 200
Nashville, TN 37215

NEW YORK
1301 Avenue of the Americas
12th Floor
New York, NY 10019

SAN FRANCISCO
255 California Street
12th Floor
San Francisco, CA 94111